Application of the ANDROMEDA Software for Prediction of the Human Pharmacokinetics of Modern Anticancer Drugs
ABSTRACT The ANDROMEDA toolkit for prediction of human clinical pharmacokinetics, based on machine learning, conformal prediction and a new physiologically-based pharmacokinetic model, was used to predict and characterize the human clinical pharmacokinetics of 12 small anticancer drugs marketed in 2021 and 2022 (molecular weight 355 to 1326 g/mol). The study is part of a series of software validations. A majority of clinical pharmacokinetic data was missing. ANDROMEDA successfully filled this gap. Most drugs were predicted/measured to have relatively complex pharmacokinetics, with limited passive permeability+efflux, high degree of plasma protein binding, significant gut-wall elimination and food interaction, biliary excretion and/or limited dissolution potential. Median, mean and maximum prediction errors for steady state volume of distribution, unbound fraction in plasma, blood-to-plasma concentration ratio, hepatic, renal and total clearance, fraction absorbed, oral bioavailability, half-life and degree of food interaction were 1.6-, 2.4- and 17-fold, respectively. Less than 3-fold errors were found for 78 % of predictions. Results are consistent with those obtained in previous validation studies and are better than with the best laboratory-based prediction methods, which validates ANDROMEDA for predictions of human clinical pharmacokinetics of modern small anticancer drugs with multi-mechanistical and challenging pharmacokinetics..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
bioRxiv.org - (2023) vom: 24. März Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fagerholm, Urban [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.1101/2023.03.18.533259 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI039024024 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI039024024 | ||
| 003 | DE-627 | ||
| 005 | 20231205145519.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230322s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2023.03.18.533259 |2 doi | |
| 035 | |a (DE-627)XBI039024024 | ||
| 035 | |a (biorXiv)10.1101/2023.03.18.533259 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fagerholm, Urban |e verfasserin |0 (orcid)0000-0001-6300-359X |4 aut | |
| 245 | 1 | 0 | |a Application of the ANDROMEDA Software for Prediction of the Human Pharmacokinetics of Modern Anticancer Drugs |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a ABSTRACT The ANDROMEDA toolkit for prediction of human clinical pharmacokinetics, based on machine learning, conformal prediction and a new physiologically-based pharmacokinetic model, was used to predict and characterize the human clinical pharmacokinetics of 12 small anticancer drugs marketed in 2021 and 2022 (molecular weight 355 to 1326 g/mol). The study is part of a series of software validations. A majority of clinical pharmacokinetic data was missing. ANDROMEDA successfully filled this gap. Most drugs were predicted/measured to have relatively complex pharmacokinetics, with limited passive permeability+efflux, high degree of plasma protein binding, significant gut-wall elimination and food interaction, biliary excretion and/or limited dissolution potential. Median, mean and maximum prediction errors for steady state volume of distribution, unbound fraction in plasma, blood-to-plasma concentration ratio, hepatic, renal and total clearance, fraction absorbed, oral bioavailability, half-life and degree of food interaction were 1.6-, 2.4- and 17-fold, respectively. Less than 3-fold errors were found for 78 % of predictions. Results are consistent with those obtained in previous validation studies and are better than with the best laboratory-based prediction methods, which validates ANDROMEDA for predictions of human clinical pharmacokinetics of modern small anticancer drugs with multi-mechanistical and challenging pharmacokinetics. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Hellberg, Sven |4 aut | |
| 700 | 1 | |a Alvarsson, Jonathan |0 (orcid)0000-0002-8682-7206 |4 aut | |
| 700 | 1 | |a Spjuth, Ola |0 (orcid)0000-0002-8083-2864 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2023) vom: 24. März |
| 773 | 1 | 8 | |g year:2023 |g day:24 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2023.03.18.533259 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 24 |c 03 | ||